Novartis AG (Novartis AG) Common Stock : $793 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Common Stock?

Novartis AG's quarterly common stock stayed the same from Sep. 2023 ($825 Mil) to Dec. 2023 ($825 Mil) but then declined from Dec. 2023 ($825 Mil) to Mar. 2024 ($793 Mil).

Novartis AG's annual common stock declined from Dec. 2021 ($901 Mil) to Dec. 2022 ($890 Mil) and declined from Dec. 2022 ($890 Mil) to Dec. 2023 ($825 Mil).

Novartis AG Common Stock Historical Data

The historical data trend for Novartis AG's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Common Stock Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

936.00

913.00

901.00

890.00

825.00

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															842.00	842.00	825.00	825.00	793.00

Novartis AG Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.